AptarGroup reported a 7% increase in reported sales and a 2% increase in core sales. Net income increased by 55% to $84 million. Earnings per share increased by 56% to $1.26, and adjusted earnings per share increased by 39% to $1.39.
Reported sales increased 7% and net income increased 55% to $84 million
Core sales increased 2% and adjusted EBITDA of $193 million increased 26% from the prior year
Pharma proprietary drug delivery systems had double-digit growth across multiple therapeutic applications
Beauty’s prestige and mass fragrance dispensing technologies had double-digit sales growth
Aptar expects continued growth in proprietary pharma drug delivery systems and improvement in the injectables division. Fragrance dispensing solutions are anticipated to finish strong in 2023. The Beauty and Closures segments will be aided by the improving environment in North America.
Visualization of income flow from segment revenue to net income